Stifel Financial’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Stifel Financial’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-318	Closed	-$96K	–	3006
2019 Q2	$96K	Sell	318 -828	-72%	-$345K	﹤0.01%	2826
2019 Q1	$526K	Buy	1,146 +211	+23%	+$92.4K	﹤0.01%	2033
2018 Q4	$429K	Sell	935 -167	-15%	-$104K	﹤0.01%	2025
2018 Q3	$1.01M	Buy	1,102 +162	+17%	+$107K	﹤0.01%	1657
2018 Q2	$550K	Buy	940 +416	+79%	+$271K	﹤0.01%	1981
2018 Q1	$343K	Buy	+524	New	+$393K	﹤0.01%	2173

Other funds holding HTGM

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Stifel Financial's HTGM Position: Q3 2019 in Review

Stifel Financial sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2019, closing a stake of 318 shares — an estimated $96K sold.

Stifel Financial first reported a position in HTGM in Q1 2018 and held it in 6 quarters. The position peaked at $1.01M in Q3 2018. 44 funds tracked by Wall St. Rank hold HTGM as of Q3 2019.

Stifel Financial reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Stifel Financial sold 318 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2019, an estimated $96K.
Stifel Financial first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 6 quarters.
Stifel Financial's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1.01M in Q3 2018.
44 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2019.

Based on Stifel Financial's 13F filing for Q3 2019, filed 13 Nov 2019.